Replimune's Breakthrough Presentations at SITC 2024
Replimune Group, Inc. (NASDAQ: REPL), a pioneering biotechnology firm focused on developing innovative oncolytic immunotherapies, is making waves in the medical community with its participation in the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024). This prestigious event will take place from November 6 to November 10, 2024, shedding light on advancements in cancer therapies.
One of the highlights for Replimune will be the late-breaking abstract featuring the IGNYTE clinical trial. This trial demonstrates a comprehensive primary analysis that the company will present orally. The significance of this analysis lies in its focus on treating patients with melanoma who have not responded to anti-PD1 treatments, a key challenge in oncology today.
Details of the Presentations
Replimune's first presentation, titled Primary analysis of the registration-intended cohort of patients with anti-PD1 failed melanoma from the IGNYTE trial of RP1 plus nivolumab, will provide insights into the clinical subgroup and initial biomarker data.
Presentation Details:
Abstract Number: 1504
Session Title: Clinical Late-Breaking Abstract Session
Date and Time: Saturday, November 9, 2024, 11:45 am – 12:45 pm CST
Presenter: Dr. Michael K. Wong, a renowned expert from the University of Texas MD Anderson Cancer Center.
Additionally, Replimune will showcase results from the ARTACUS clinical trial, which investigates the use of RP1 monotherapy in solid organ transplant patients facing advanced cutaneous malignancies. This study's results will be part of an encore poster presentation.
In-Depth Look at the ARTACUS Trial
The ARTACUS trial is particularly significant because it addresses the unique challenges faced by patients who have received organ transplants and now deal with advanced skin cancers. The findings from this study will help illuminate the safety and efficacy of RP1 in this vulnerable patient population.
Presentation Details:
Abstract Number: 693
Date: Friday, November 8, 2024
Presenter: Dr. Diwakar Davar from UPMC Hillman Cancer Center.
About Replimune Group, Inc.
Founded in 2015 and based in Woburn, MA, Replimune Group is on a mission to transform cancer treatment through its proprietary RPx platform. This innovative platform harnesses a powerful HSV-1 backbone, designed to maximize immunogenic cell death, facilitating systemic anti-tumor immune responses. The RPx candidates are crafted to provide direct tumor killing while also modifying the tumor microenvironment to promote a robust immune response.
Replimune’s therapies aim to work synergistically with existing cancer treatments, thus offering a versatile approach that could be combined with an array of other therapeutic options. The ongoing research endeavors and clinical trials at Replimune signal hope for patients struggling with difficult-to-treat forms of cancer.
Investor and Media Inquiries
For investors, Chris Brinzey from ICR Westwicke can be reached at 339.970.2843 or via email at chris.brinzey@westwicke.com.
For media inquiries, Arleen Goldenberg at Replimune is available at 917.548.1582 or media@replimune.com.
Frequently Asked Questions
What is the main focus of Replimune's presentations at SITC 2024?
Replimune will focus on the IGNYTE clinical trial results and the ARTACUS study, showcasing advancements in their oncolytic immunotherapy research.
Who will present the findings from the IGNYTE trial?
Dr. Michael K. Wong will lead the presentation regarding the IGNYTE trial's primary analysis.
What are the implications of the ARTACUS trial findings?
The ARTACUS trial aims to assess the efficacy and safety of RP1 in organ transplant patients with advanced cutaneous malignancies, addressing a critical need in this patient population.
When and where is the SITC 2024 event taking place?
The SITC 2024 event will occur from November 6 to November 10, 2024, in Houston, Texas.
How can investors and media contact Replimune?
Investors can contact Chris Brinzey at ICR Westwicke, while media inquiries can be directed to Arleen Goldenberg at Replimune.
